PI3K/Akt/mTOR signaling pathway and breast cancer – from molecular targets to clinical aspects


Doc. MUDr. Jana Dvořáčková, Ph.D., MIAC1,2,3; Mgr. Barbora Kubová1; Mgr. Jarmila Šimová1; RNDr. Magdalena Uvírová, Ph.D.1,3

1 CGB laboratoř, a.s.

2 Katedra intenzivní medicíny, urgentní medicíny a forenzních oborů, LF OU, Ostrava

3 Ústav patologie LF OU, Ostrava



Breast cancer is one of the most common malignancies in women. The PI3K/Akt/mTOR signaling pathway plays an important role in several cellular processes involved in proliferation, metabolism, cell growth, and survival. Alterations in this signaling pathway have been found in a variety of tumors, including breast cancer. Constitutive activation of the PI3K/Akt/mTOR signaling pathway plays a key role in tumor pathogenesis and resistance to conventional therapy. In connection with the newly approved treatment with PI3K inhibitors, the determination of PIK3CA mutation status as a predictive marker is also gaining in importance.


Key words

breast cancer, PI3K/Akt/mTOR signaling pathway, PIK3CA mutations, PI3K inhibitors



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...